Associate Professor
Adjunct Associate Professor

MEMPHIS TN 381033403
Tel: (901) 448-2403


  • PostDoc, Baylor College of Medicine, Molecular Pharmacology
  • Ph.D., University of Madras, India, Biochemistry

Research Keywords

Androgen Receptor, Prostate Cancer, Breast Cancer, Obesity, Estrogen Receptor

Research Interest/Specialty

After post-doctoral fellowship at Baylor College of Medicine in 2004, Dr. Narayanan went on to perform drug discovery research in biopharmaceutical industry. He served as Senior Scientist and as Director of Drug Discovery in industry. In 2014, he transitioned back to academia and joined the University of Tennessee, Memphis as tenure-track Associate Professor in the Department of Medicine. Dr. Narayanan has published over 40 peer-reviewed research articles and has contributed to about 70 patent applications.

Dr. Narayanan''s research interests are to discover drugs targeting steroid hormone receptor family members and to understand the mechanism of action of therapeutic proteins using chemical biology approach.


  1. Ponnusamy, S, Sullivan, RD, You, D, Zafar, N, He Yang, C, Thiyagarajan, T, Johnson, DL, Barrett, ML, Koehler, NJ, Star, M, Stephenson, EJ, Bridges, D, Cormier, SA, Pfeffer, LM, Narayanan, R. Androgen Receptor Agonists Increase Lean Mass, Improve Cardiopulmonary Functions, and Extend Survival in Preclinical Models of Duchenne Muscular Dystrophy. Hum Mol Genet, 2017.
  2. Ponnusamy, S, Tran, QT, Harvey, I, Smallwood, HS, Thiyagarajan, T, Banerjee, S, Johnson, DL, Dalton, JT, Sullivan, RD, Miller, DD, Bridges, D, Narayanan, R. Pharmacologic activation of estrogen receptor β increases mitochondrial function, energy expenditure, and brown adipose tissue. FASEB J, 31 (1), 266-281, 2017.
  3. Narayanan, R, Dalton, JT. Androgen Receptor: A Complex Therapeutic Target for Breast Cancer. Cancers (Basel), 8 (12), 2016.
  4. Pedram, A, Razandi, M, Narayanan, R, Levin, ER. Estrogen receptor beta signals to inhibition of cardiac fibrosis. Mol Cell Endocrinol, 434, 57-68, 2016.
  5. Pi, M, Kapoor, K, Wu, Y, Ye, R, Senogles, SE, Nishimoto, SK, Hwang, DJ, Miller, DD, Narayanan, R, Smith, JC, Baudry, J, Quarles, LD. Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral Tissues. Mol Endocrinol, 29 (12), 1759-73, 2015.
  6. Park, K, Dalton, JT, Narayanan, R, Barbieri, CE, Hancock, ML, Bostwick, DG, Steiner, MS, Rubin, MA. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol, 32 (3), 206-11, 2014.
  7. Yepuru, M, Wu, Z, Kulkarni, A, Yin, F, Barrett, CM, Kim, J, Steiner, MS, Miller, DD, Dalton, JT, Narayanan, R. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res, 19 (20), 5613-25, 2013.
  8. Narayanan, R, Edwards, DP, Weigel, NL. Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol, 25 (8), 2885-98, 2005.
  9. Narayanan, R, Adigun, AA, Edwards, DP, Weigel, NL. Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol, 25 (1), 264-77, 2005.
  10. Narayanan, R, Sepulveda, VA, Falzon, M, Weigel, NL. The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. J Biol Chem, 279 (45), 47298-310, 2004.
  11. Narayanan, R, Allen, MR, Gaddy, D, Bloomfield, SA, Smith, CL, Weigel, NL. Differential skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D3 and its analog, seocalcitol (EB1089). Bone, 35 (1), 134-43, 2004.
  12. Narayanan, R, Smith, CL, Weigel, NL. Vector-averaged gravity-induced changes in cell signaling and vitamin D receptor activity in MG-63 cells are reversed by a 1,25-(OH)2D3 analog, EB1089. Bone, 31 (3), 381-8, 2002.